- Its medical communications application, Bleepa, has made appreciable progress since its launch in September 2019.
- The company’s TexRAD technology will require to be supported by more clinical data in order to satisfy US FDA.
- The company has incorporated some modifications into TexRAD research after taking feedback from customers.
- On 18th November 2019, FDBK shares were trading at GBX 1.05 at GMT 10:52 AM, up 0.03 points or 2.44% from the previous day’s closing price level.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.